EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SMAD3 promotes expression and activity of the androgen receptor in prostate cancer

Hee-Young Jeon, Majid Pornour, Hyunju Ryu, Sudeep Khadka, Rui Xu, Jihyun Jang, Deqiang Li, Hegang Chen, Arif Hussain, Ladan Fazli, Martin Gleave, Xuesen Dong und 4 weitere

Nucleic Acids Research · 11.04.2023 · 51 (6) · 2655-2670

DOI: 10.1093/nar/gkad043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 02.02.2023. Verfasst von Hee-Young Jeon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Smad3 Protein. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCI NIH HHS, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of androgen receptor (AR) is the primary cause of castration-resistant prostate cancer, although mechanisms upregulating AR transcription in this context are not well understood. Our RNA-seq studies revealed that SMAD3 knockdown decreased levels of AR and AR target genes, whereas SMAD4 or SMAD2 knockdown had little or no effect. ChIP-seq analysis showed that SMAD3 knockdown decreased global binding of AR to chromatin. Mechanistically, we show that SMAD3 binds to intron 3 of the AR gene to promote AR expression. Targeting these binding sites by CRISPRi reduced transcript levels of AR and AR targets. In addition, ∼50% of AR and SMAD3 ChIP-seq peaks overlapped, and SMAD3 may also cooperate with or co-activate AR for AR target expression. Functionally, AR re-expression in SMAD3-knockdown cells partially rescued AR target expression and cell growth defects. The SMAD3 peak in AR intron 3 overlapped with H3K27ac ChIP-seq and ATAC-seq peaks in datasets of prostate cancer. AR and SMAD3 mRNAs were upregulated in datasets of metastatic prostate cancer and CRPC compared with primary prostate cancer. A SMAD3 PROTAC inhibitor reduced levels of AR, AR-V7 and AR targets in prostate cancer cells. This study suggests that SMAD3 could be targeted to inhibit AR in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantSmad3 ProteinHumansMaleCell Line, TumorGene Expression Regulation, NeoplasticProstateReceptors, Androgen

Substanzen

Receptors, AndrogenSmad3 ProteinSMAD3 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD, USA.
  • Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
  • Institute of Marine and Environmental Technology, University of Maryland, Baltimore, MD, USA.
  • Department of Cardiac Surgery, University of Maryland, Baltimore, MD, USA.
  • Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, USA.
  • Baltimore VA Medical Center, Baltimore, MD, USA.

ORCID-Profile: Qianben Wang, Jianfei Qi

Förderung

  • BLRD VA
  • NCI NIH HHS
  • NCI
  • Merit Review Award
  • Medical Research Service
  • U.S. Department of Veterans Affairs
  • Prostate Cancer Foundation
  • Maryland Department of Health's Cigarette Restitution Fund

Zitieren

APA

Jeon, H. Y., Pornour, M., Ryu, H., Khadka, S., Xu, R., Jang, J., Li, D., Chen, H., Hussain, A., Fazli, L., Gleave, M., Dong, X., Huang, F., Wang, Q., Barbieri, C., & Qi, J. (2023). SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Research, 51(6), 2655-2670. https://doi.org/10.1093/nar/gkad043

Vancouver

Jeon HY, Pornour M, Ryu H, Khadka S, Xu R, Jang J, et al. SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Research. 2023;51(6):2655-2670. doi:10.1093/nar/gkad043

BibTeX
@article{Jeon2023,
  author = {Jeon, Hee-Young and Pornour, Majid and Ryu, Hyunju and Khadka, Sudeep and Xu, Rui and Jang, Jihyun and Li, Deqiang and Chen, Hegang and Hussain, Arif and Fazli, Ladan and Gleave, Martin and Dong, Xuesen and Huang, Furong and Wang, Qianben and Barbieri, Christopher and Qi, Jianfei},
  title = {SMAD3 promotes expression and activity of the androgen receptor in prostate cancer},
  journal = {Nucleic Acids Research},
  year = {2023},
  volume = {51},
  number = {6},
  pages = {2655--2670},
  doi = {10.1093/nar/gkad043}
}
Kostenlos starten →